Werewolf Therapeutics, Inc. Common Stock (HOWL)
Werewolf Therapeutics, Inc. (HOWL) is a biotechnology company focused on developing targeted immunotherapies for cancer. The company aims to create novel therapies that stimulate the immune system to fight tumors more effectively, utilizing innovative approaches in cytokine and immunomodulatory drug design.
Company News
Werewolf Therapeutics will present three scientific posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting, highlighting research on conditionally activated immune therapeutics for cancer treatment.
Werewolf Therapeutics reported Q2 2025 results with no revenue, continued investment in cancer immunotherapy research, and focus on advancing clinical trials for WTX-124 and WTX-330 drug candidates.
Ratings for Werewolf Therapeutics (NASDAQ:HOWL) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bulli...
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Penny stocks to buy according to these insiders in January. The post 4 Penny Stocks To Buy In January According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.